AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02252601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pure tone Audiogram
Study NCT02118597 — intervention group
Intervention type: DRUG
Intervention: Boceprevir
Description: Boceprevir administered according to corresponding summary of product characteristics (SmPC).
Study NCT00638989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 150 mg (intravenous)
Description: A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
Study NCT00638989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 150 mg (subcutaneous)
Description: A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
Study NCT00638989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 300 mg (subcutaneous)
Description: A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
Study NCT01228435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
Study NCT02886442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)
Study NCT02886442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip
Study NCT02118597 — intervention group
Intervention type: DRUG
Intervention: Simeprevir
Description: Simeprevir administered according to corresponding summary of product characteristics (SmPC).
Study NCT02118597 — intervention group
Intervention type: DRUG
Intervention: Pegylated Interferon (Peginterferon) Alfa-2a
Description: Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
Study NCT00660530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate crushed powder
Description: Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
Study NCT02118597 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to corresponding summary of product characteristics (SmPC).
Study NCT03184363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum A Toxin
Description: Clostridium Botulinum A Toxin
Study NCT01355263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron and vitamin a
Study NCT01283906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuGard
Description: Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
Study NCT01283906 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Rinse
Description: Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
Study NCT01903395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling
Description: Nurse-led telephone counselling to double the utilization of preventive colonoscopy
Study NCT01512849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 Low
Description: Low
Study NCT01512849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 High
Description: High
Study NCT04659447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: 36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
Study NCT02102126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Study NCT02159118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual bone marrow aspiration and biopsy device
Description: Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
Study NCT02159118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered bone marrow aspiration and biopsy device
Description: Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
Study NCT01742572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Change in dietary intake
Study NCT01742572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Change in dietary intake
Study NCT04336371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
Study NCT02523131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceM
Description: The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
Study NCT02523131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic insulin pump 640G
Description: Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
Study NCT03671707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief AWARD advice
Description: Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline
Study NCT03671707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy sampling
Description: Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
Study NCT03671707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active referral
Description: Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
Study NCT03671707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very brief advice
Description: Subjects will receive general advice to quit
Study NCT03671707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: Subjects will receive a standard leaflet on perinatal smoking by Department of Health
Study NCT04504890 — intervention group
Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Nystagmograph used to measure eye movement
Study NCT01296074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: 500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Study NCT01890395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
Study NCT03097575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG Intervention
Description: Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
Study NCT03097575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: A near-infrared camera device will be used to detect indocyanine green following injection.
Study NCT04490980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butorphanol
Description: Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
Study NCT00580125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 5 mg, oral capsule, once daily for 21 days
Study NCT00580125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral capsule, once daily for 21 days
Study NCT00580125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole 15 mg, oral capsule, once daily for 21 days
Study NCT00580125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 15 mg, oral capsule, once daily for 21 days
Study NCT01183130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compliance monitoring with electronic device
Description: Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
Study NCT00580125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 2 mg, oral capsule, once daily for 21 days
Study NCT00320749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Will be give on days 8-21
Study NCT00320749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Will be given on days 1 and 8,
Study NCT00320749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A fixed dose rate will be give on days 8 and 15.
Study NCT03454867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Study NCT03100370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted training of arm and hand functions
Description: 70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
Study NCT03454867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard acute ischemic stroke treatment
Study NCT01857349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlora Prep
Description: Surgical Scrub skin preparation
Study NCT03454867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard acute ischemic stroke treatment
Study NCT03627312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
Study NCT03627312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fruit juice drink only
Study NCT01857349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dura Prep
Description: Surgical Scrub skin preparation
Study NCT03627312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme
Study NCT01924312 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Heart Health Intervention
Description: A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
Study NCT01924312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Health Intervention
Description: A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
Study NCT03627312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme
Study NCT03627312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme
Study NCT01170754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 and Gatorade
Description: 255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
Study NCT01170754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely 4 liters
Description: Golytely 4 liters
Study NCT00974909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC neuromodulation system
Description: Urgent PC neuromodulation system
Study NCT00974909 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Urgent PC neuromodulation system
Description: Urgent PC neuromodulation system (sham)
Study NCT01395433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 2 x 10 mg, single dose
Study NCT01562405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: Injection every 28 days, dose escalation levels from 15-45 mg
Study NCT01562405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 to 25 mg days 1-21, given orally
Study NCT01395433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 2 x 10 mg, single dose
Study NCT01395433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 1 x 20 mg, single dose
Study NCT03465592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV
Study NCT03864471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCOACDM
Description: The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
Study NCT03864471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
Study NCT01689129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01689129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901) (Lantus)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01108133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg HydrocortisoneHöchst
Description: 10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
Study NCT01108133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
Study NCT01108133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01830660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablets
Study NCT01830660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04357392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
Study NCT04357392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
Study NCT02450032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study NCT03071575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-rubella (MR) vaccine at 6 and 9 months
Description: Arm A will receive MR vaccine dose at 6 and 9 months of age
Study NCT03071575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-rubella (MR) vaccine at 9 months
Description: Arm A will receive MR vaccine dose at 9 months of age
Study NCT01290640 — intervention group
Intervention type: DEVICE
Intervention: DePuy fixed-bearing Total Condylar III (TC3) TKA
Study NCT01290640 — intervention group
Intervention type: DEVICE
Intervention: DePuy PFC Rotating Platform TC3 TKA
Study NCT01562405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg days 1,8,15,22; given orally
Study NCT01562405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg daily on days 1-21
Study NCT00933920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Study NCT01025570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Bosutinib
Description: Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
Study NCT01183130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliance monitoring with electronic device
Description: Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
Study NCT02743546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvortuxizumab
Description: Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
Study NCT03172091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eNose (electronic nose)
Description: Collection of exhaled breath for an immediate analysis by electronic nose
Study NCT03172091 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: eNose (electronic nose)
Description: Collection of exhaled breath for an immediate analysis by electronic nose
Study NCT03172091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrometry
Description: Collection of exhaled breath for an immediate analysis by mass spectrometry
Study NCT03172091 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectrometry
Description: Collection of exhaled breath for an immediate analysis by mass spectrometry
Study NCT02000011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive geriatric assessment (CGA)
Study NCT02000011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive geriatric assessment (CGA)
Study NCT02000011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention plan (GIP)
Study NCT03398265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Navigation (Intervention)
Description: Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.